[Anti-CD19-liposomes encapsulated domain III of pseudomonas exotoxin in the targeting of human B lymphoma].
OBJECTIVE
To evaluate the targeting ability and cytotoxicity of domain III of pseudomonas exotoxin encapsulated in anti-CD19-immunoliposomes to lymphoma cells in vitro and in vivo.


METHODS
Binding ability of anti-CD19 immunoliposomes to B lymphoma cells was detected by binding assay. MTT assay was used to detect the cytotoxicity of free domain III and domain III encapsulated in anti-CD19-immunoliposomes against B lymphoma cells. An in vivo therapeutic study of domain III formulated in immunoliposomes on human B lymphoma was detected in a murine model.


RESULTS
The cytotoxicity of free domain III disappeared when domain I and II were deleted. When domain III was encapsulated into anti-CD19-immunoliposomes, the cytotoxicity of immunoliposomes against tumor cells were significantly increased. Treatment, using this formulation, of mice inoculated with B lymphoma could enhance the survival time.


CONCLUSIONS
Anti-CD19-immunoliposomes, as drug carriers, can specifically recognize B lymphoma cells and deliver non-toxic domain III into the tumor cells. This formulation of domain III might be an effective anti-tumor agent.
Ma
Jie
J
National Laboratory of Molecular Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China.
Cao
Li-Ren
LR
D000818:Animals; D018941:Antigens, CD19 / Q000276:immunology; D004195:Disease Models, Animal; D004337:Drug Carriers; D016503:Drug Delivery Systems; D005098:Exotoxins / Q000627:therapeutic use*; D006801:Humans; D008081:Liposomes; D008223:Lymphoma / Q000473:pathology; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D011549:Pseudomonas / Q000737:chemistry*; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
D018941:Antigens, CD19; D004337:Drug Carriers; D005098:Exotoxins; D008081:Liposomes